Sevoflurane Postconditioning Inhibits Pulmonary Apoptosis via PI3K/AKT in Dog Cardiopulmonary Bypass Model
DOI:
https://doi.org/10.1532/hsf.4721Keywords:
cardiopulmonary bypass, Ischemia-reperfusion, lung apoptosis, PI3K/Akt pathway, Sevoflurane postconditioningAbstract
Aims: The study aimed to investigate the protective effects and regulatory mechanism of sevoflurane postconditioning (SPC) in pulmonary apoptosis induced by cardiopulmonary bypass (CPB).
Methods: Twenty-four healthy dogs were divided into a control (C group), ischemia/reperfusion (I/R group), sevoflurane postconditioning (S group), and wortmannin group (S+W group). At 10 min after the establishment of CPB, the left pulmonary artery was blocked. When the pulmonary artery was reopened, 2% sevoflurane was administered. Wortmannin was delivered 10 min before the pulmonary artery was open. Before thoracotomy was implemented (T1), when the artery was reopened (T2) and 2 h after CPB (T3), blood and the inferior lobe of the left lung were isolated and subjected to gas analysis, pathological examination, western blot, and TUNEL staining.
Results: No obvious changes were observed in the C group throughout the experiment. The conditions of all treated groups progressively deteriorated, and no difference could be found except in the number of apoptotic cells of T3 between the S+W and I/R groups. At T2, the treated groups showed similar conditions. At T3, the lung function and structure of the S group were improved in I/R and S+W groups. The S group showed the highest p-Akt expression, the lowest cleaved-caspase 3 expression, and apoptotic cell percentage.
Conclusions: Ischemia-reperfusion of the lung during CPB reduces lung function and injures the pulmonary structure via inducing lung apoptosis. Sevoflurane postconditioning preserves lung function and structure by alleviating apoptosis via activation of PI3K/Akt.
References
Denault AY, Deschamps A, Couture P. 2010. Intraoperative hemodynamic instability during and after separation from cardiopulmonary bypass. Semin Cardiothorac Vasc Anesth. 14(3):165-82.
Fischer S, Cassivi SD, Xavier AM, Cardella JA, Cutz E, Xavier AM, et al. 2000. Cell death in human lung transplantation: Apoptosis induction in human lungs during ischemia and after transplantation. Ann Surg. 231:424–431.
Inamura Y, Miyamae M, Sugioka S, Domae N, Kotani J. 2010. Sevoflurane postconditioning prevents activation of caspase 3 and 9 through antiapoptotic signaling after myocardial ischemia-reperfusion. J Anesth. 24(2):215-24.
Jeon YT, Hwang JW, Lim YJ, Kim AN, Park HP. 2013. A combination of sevoflurane postconditioning and albumin increases Bcl-2 expression after transient global cerebral ischemia compared with either sevoflurane postconditioning or albumin alone. J Neurosurg Anesthesiol. 25(1):43-50.
Kiessling AH, Guo FW, Gökdemir Y, Thudt M, Reyher C, Scherer M, et al. 2014. The influence of selective pulmonary perfusion on the inflammatory response and clinical outcome of patients with chronic obstructive pulmonary disease undergoing cardiopulmonary bypass. Interact Cardiovasc Thorac Surg. 18(6):732-9.
Klass O, Fischer UM, Antonyan A, Bosse M, Fischer JH, et al. 2007. Pneumocyte apoptosis induction during cardiopulmonary bypass: effective prevention by radical scavenging using N-acetylcysteine. J Invest Surg. 20: 349–356.
Lee H, Park YH, Jeon YT, Hwang JW, Lim YJ, Kim E, et al. 2015. Sevoflurane post-conditioning increases nuclear factor erythroid 2-related factor and haemoxygenase-1 expression via protein kinase C pathway in a rat model of transient global cerebral ischaemia. Br J Anaesth. 114(2):307-18.
Li D, Huang B, Liu J, Li L, Li X. 2013. Decreased brain K(ATP) channel contributes to exacerbating ischemic brain injury and the failure of neuroprotection by sevoflurane post-conditioning in diabetic rats. PLoS One. 26;8(8):e73334.
Li J, Zhou J, Zhang D, Song D, She J, Bai C. 2015. Bone marrow-derived mesenchymal stem cells enhance autophagy via PI3K/AKT signalling to reduce the severity of ischaemia/reperfusion-induced lung injury. J Cell Mol Med. 19(10):2341-51.
Li R, Xu X, Chen C, Yu X, Edin ML, Degraff LM, et al. 2012. Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice. Prostaglandins Other Lipid Mediat. 2012, 99(3-4):68-78.
Li X, Luo P, Wang F, Yang Q, Li Y, Zhao M, et al. 2014. Inhibition of N-myc downstream-regulated gene-2 is involed in an astrocyte-specific neuroproction induced by sevoflurane preconditioning. Anesthesiology. 121(3):549-62.
Liu C, Shen Z, Liu Y, Peng J, Miao L, Zeng W, Li Y. 2015. Sevoflurane protects against intestinal ischemia-reperfusion injury partly by phosphatidylinositol 3 kinases/Akt pathway in rats. Surgery. 157(5):924-33.
Meybohm P, Gruenewald M, Albrecht M, Müller C, Zitta K, Foesel N, et al. 2011. Pharmacological postconditioning with sevoflurane after cardiopulmonary resuscitation reduces myocardial dysfunction. Crit Care. 15(5): R241.
Ren XP, Wu J, Wang X, Sartor MA, Qian J, Jones K, et al. 2009. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation. 119(17):2357-66.
Rodríguez A, Taurà P, García Domingo MI, Herrero E, Camps J, Forcada P, et al. 2015. Hepatic cytoprotective effect of ischemic and anesthetic preconditioning before liver resection when using intermittent vascular inflow occlusion: a randomized clinical trial. Surgery. 157(2):249-59.
Slottosch I, Liakopoulos O, Kuhn E, Deppe A, Lopez-Pastorini A, Schwarz D, et al. 2014. Controlled lung reperfusion to reduce pulmonary ischaemia/reperfusion injury after cardiopulmonary bypass in a porcine model.Interact Cardiovasc Thorac Surg. 19(6):962-70.
Steurer M, Schläpfer M, Steurer M, Z'graggen BR, Booy C, Reyes L, et al. 2009. The volatile anaesthetic sevoflurane attenuates lipopolysaccharide-induced injury in alveolar macrophages. Clin Exp Immunol.155(2):224-30.
Tsai HJ, Huang SS, Tsou MT, Wang HT, Chiu JH. 2015. Role of Opioid Receptors Signaling in Remote Electrostimulation - Induced Protection against Ischemia/Reperfusion Injury in Rat Hearts. PLoS One. 10(10):e0138108.
Van Putte BP, Kesecioglu J, Hendriks JM, Persy VP, van Marck E, van Schil P, et al. 2005. Cellular infiltrates and injury evaluation in a rat model of warm pulmonary ischemia-reperfusion. Crit Care. 9: R1–R8.
Wang C, Xie H, Liu X, Qin Q, Wu X, Liu H, et al. 2010. Role of nuclear factor-κB in volatile anaesthetic preconditioning with sevoflurane during myocardial ischaemia/reperfusion. Eur J Anaesthesiol. 27(8):747-56.
Wang H, Shi H, Yu Q, Chen J, Zhang F, Gao Y. 2016. Sevoflurane Preconditioning Confers Neuroprotection via Anti-apoptosis Effects. Acta Neurochir Suppl. 121:55-61.
Wei K, Liu L, Xie F, Hao X, Luo J, Min S. 2015. Nerve growth factor protects the ischemic heart via attenuation of the endoplasmic reticulum stress induced apoptosis by activation of phosphatidylinositol 3-kinase. Int J Med Sci. 12(1):83-91.
White LE, Cui Y, Shelak CM, Lie ML, Hassoun HT. 2012. Lung endothelial cell apoptosis during ischemic acute kidney injury. Shock. 38(3):320-7.
Yang K, Gao B, Wei W, Li Z, Pan L, Zhang J, et al. 2015. Changed profile of microRNAs in acute lung injury induced by cardio-pulmonary bypass and its mechanism involved with SIRT1. Int J Clin Exp Pathol. 8(2):1104-15.
Yao H, Han X, Han X. 2014. The cardioprotection of the insulin-mediated PI3K/Akt/mTOR signaling pathway. Am J Cardiovasc Drugs. 14(6):433-42.
Ye Z, Xia P, Cheng ZG, Guo Q. 2015. Neuroprotection induced by sevoflurane-delayed post-conditioning is attributable to increased phosphorylation of mitochondrial GSK-3β through the PI3K/Akt survival pathway. J Neurol Sci. 348(1-2):216-25.
Yu Y, Gao M, Li H, Zhang F, Gu C. 2013. Pulmonary artery perfusion with anti-tumor necrosis factor alpha antibody reduces cardiopulmonary bypass-induced inflammatory lung injury in a rabbit model. PLoS One. 8(12): e83236.
Zhang J, Wang C, Yu S, Luo Z, Chen Y, Liu Q. 2014. Sevoflurane Postconditioning Protects Rat Hearts against Ischemia-Reperfusion Injury via the Activation of PI3K/AKT/mTOR Signaling. Sci Rep. 4:7317.
Zhang L, Zhao X, Jiang X. 2015. Sevoflurane Post-conditioning Protects Primary Rat Cortical Neurons Against Oxygen-Glucose Deprivation/Resuscitation: Roles of Extracellular Signal-Regulated Kinase 1/2 and Bid, Bim, Puma. Neurochem Res. 40(8):1609-19.
Zhang LM, Zhao XC, Sun WB, Li R, Jiang XJ. 2015. Sevoflurane post-conditioning protects primary rat cortical neurons against oxygen-glucose deprivation/resuscitation via down-regulation in mitochondrial apoptosis axis of Bid, Bim, Puma-Bax and Bak mediated by Erk1/2. J Neurol Sci. 357(1-2):80-7.
Zhang Y, Tian SY, Li YW, Zhang L, Yu JB, Li J, et al. 2015. Sevoflurane preconditioning improving cerebral focal ischemia-reperfusion damage in a rat model viaPI3K/Akt signaling pathway. Gene. 569(1):60-5.
Zhao S, Wu J, Zhang L, Ai Y. 2014. Postconditioning with sevoflurane induces heme oxygenase-1 expression via the PI3K/Akt pathway in lipopolysaccharide-induced acute lung injury. Mol Med Rep. Jun;9(6):2435-40.
Zhou L, Zhao D, An H, Zhang H, Jiang C, Yang B. 2015. Melatonin prevents lung injury induced by hepatic ischemia-reperfusion through anti-inflammatory and anti-apoptosis effects. Int Immunopharmacol. pii: S1567-5769(15)30146-6.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
